Type 2 diabetes, thiazolidinediones, and cardiovascular risk

Clare Taylor, Frederick Hobbs

    Research output: Contribution to journalArticle

    16 Citations (Scopus)


    Type 2 diabetes is a common disorder with an increased risk of macrovascular complications. Achieving adequate glycaemic control is an important aim of therapy. Thiazolidinediones, or glitazones, have been used for the treatment of diabetes for a decade. Rosiglitazone and pioglitazone are currently available, however recent concerns around cardiovascular safety have led to restrictions on their use. Initial trials showed treatments with glitazones improved glycaemic control, however long-term outcomes such as cardiovascular events were not measured. Evidence from more recent trials suggests rosiglitazone is associated with an increased risk of cardiovascular events and both glitazones are associated with higher rates of heart failure. This article discusses the evidence behind these concerns and the most recent guidance on use of thiazolidinediones in clinical practice.
    Original languageEnglish
    Pages (from-to)520-524
    Number of pages5
    JournalBritish Journal of General Practice
    Issue number564
    Publication statusPublished - 1 Jul 2009


    • glitazones
    • heart failure
    • thiazolidinediones
    • cardiovascular risk
    • type 2 diabetes


    Dive into the research topics of 'Type 2 diabetes, thiazolidinediones, and cardiovascular risk'. Together they form a unique fingerprint.

    Cite this